Pinzour doctors signed her up for a new kind of treatment. It uses the patient's own tumor-fighting T-cells, called tumor-infiltrating lymphocytes, or TILs. "By taking those TILs out of the ...

Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...

Leveraging tumor organoids to model drug response in clear cell renal cell carcinoma. % Reactive Fragments 65.2 ± 26.8 43.0 ± 46.2 % CD56 + of TIL Expansion 14.1 ± 26.2 9.8 ± 4.6 % CD3 + of TIL ...

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You accept for the main domain ...

This study shows that engineered E. coli Nissle 1917 producing indole-3-acetic acid (IAA), an AhR agonist, modulate the tumor ...

Genome-scale metabolic reconstruction of urinary microbiome: Pathway for personalized medicine. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the ...

The biotechnology company intends to more than double its current production capacity at the Navy Yard, interim CEO Fred Vogt ...

However, cancer cells have developed immune evasion strategies, leading to poor treatment responses ... weakening tumor-infiltrating lymphocytes (TILs), the immune cells that attack tumor.

Cell and gene therapies have undergone notable milestones in the last 12 months, with solid tumors and diabetes treatments.

PhD Defense: Predicting immunotherapy outcomes in advanced melanoma; Clinical, radiological, and pathological approaches ...

KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including ...

The multivariable analysis, including clinicopathological factors, presence of tumor-infiltrating lymphocytes, and type of treatment, demonstrated that RAD51 maintained its prognostic capacity by ...